James A de Lemos1, Colby R Ayers2, Benjamin D Levine2, Christopher R deFilippi2, Thomas J Wang2, W Gregory Hundley2, Jarett D Berry2, Stephen L Seliger2, Darren K McGuire2, Pamela Ouyang2, Mark H Drazner2, Matthew Budoff2, Philip Greenland2, Christie M Ballantyne2, Amit Khera2. 1. From Departments of Medicine (J.A.d.L., B.L., J.P.B., D.K.M., M.H.D., A.K.) and Clinical Sciences (C.R.A., J.D.B., D.K.M.), University of Texas Southwestern Medical Center, Dallas; Institute for Exercise and Environmental Medicine, Texas Health Presbyterian, Dallas (B.L.); Inova Heart and Vascular Institute, Fall Church, VA (C.R.d.); Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (T.J.W.); Departments of Medicine and Radiological Sciences, Wake Forest Health Sciences, Winston-Salem, NC (W.G.H.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.L.S.); The Johns Hopkins University School of Medicine, Baltimore, MD (P.O.); Los Angeles Biomedical Research Institute, CA (M.B.); Departments of Preventive Medicine and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (P.G.); and Baylor College of Medicine, Houston, TX (G.M.B.). james.delemos@utsouthwestern.edu. 2. From Departments of Medicine (J.A.d.L., B.L., J.P.B., D.K.M., M.H.D., A.K.) and Clinical Sciences (C.R.A., J.D.B., D.K.M.), University of Texas Southwestern Medical Center, Dallas; Institute for Exercise and Environmental Medicine, Texas Health Presbyterian, Dallas (B.L.); Inova Heart and Vascular Institute, Fall Church, VA (C.R.d.); Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (T.J.W.); Departments of Medicine and Radiological Sciences, Wake Forest Health Sciences, Winston-Salem, NC (W.G.H.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.L.S.); The Johns Hopkins University School of Medicine, Baltimore, MD (P.O.); Los Angeles Biomedical Research Institute, CA (M.B.); Departments of Preventive Medicine and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (P.G.); and Baylor College of Medicine, Houston, TX (G.M.B.).
Abstract
BACKGROUND: Current strategies for cardiovascular disease (CVD) risk assessment among adults without known CVD are limited by suboptimal performance and a narrow focus on only atherosclerotic CVD (ASCVD). We hypothesized that a strategy combining promising biomarkers across multiple different testing modalities would improve global and atherosclerotic CVD risk assessment among individuals without known CVD. METHODS: We included participants from MESA (Multi-Ethnic Study of Atherosclerosis) (n=6621) and the Dallas Heart Study (n=2202) who were free from CVD and underwent measurement of left ventricular hypertrophy by ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein. Associations of test results with the global composite CVD outcome (CVD death, myocardial infarction, stroke, coronary or peripheral revascularization, incident heart failure, or atrial fibrillation) and ASCVD (fatal or nonfatal myocardial infarction or stroke) were assessed over >10 years of follow-up. Multivariable analyses for the primary global CVD end point adjusted for traditional risk factors plus statin use and creatinine (base model). RESULTS: Each test result was independently associated with global composite CVD events in MESA after adjustment for the components of the base model and the other test results (P<0.05 for each). When the 5 tests were added to the base model, the c-statistic improved from 0.74 to 0.79 (P=0.001), significant integrated discrimination improvement (0.07, 95% confidence interval [CI] 0.06-0.08, P<0.001) and category free net reclassification improvement (0.47; 95% CI, 0.38-0.56; P=0.003) were observed, and the model was well calibrated (χ2=12.2, P=0.20). Using a simple integer score counting the number of abnormal tests, compared with those with a score of 0, global CVD risk was increased among participants with a score of 1 (adjusted hazard ratio, 1.9; 95% CI, 1.4-2.6), 2 (hazard ratio, 3.2; 95% CI, 2.3-4.4), 3 (hazard ratio, 4.7; 95% CI, 3.4-6.5), and ≥4 (hazard ratio, 7.5; 95% CI, 5.2-10.6). Findings replicated in the Dallas Health Study were similar for the ASCVD outcome. CONCLUSIONS: Among adults without known CVD, a novel multimodality testing strategy using left ventricular hypertrophy by ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein significantly improved global CVD and ASCVD risk assessment.
BACKGROUND: Current strategies for cardiovascular disease (CVD) risk assessment among adults without known CVD are limited by suboptimal performance and a narrow focus on only atherosclerotic CVD (ASCVD). We hypothesized that a strategy combining promising biomarkers across multiple different testing modalities would improve global and atherosclerotic CVD risk assessment among individuals without known CVD. METHODS: We included participants from MESA (Multi-Ethnic Study of Atherosclerosis) (n=6621) and the Dallas Heart Study (n=2202) who were free from CVD and underwent measurement of left ventricular hypertrophy by ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein. Associations of test results with the global composite CVD outcome (CVD death, myocardial infarction, stroke, coronary or peripheral revascularization, incident heart failure, or atrial fibrillation) and ASCVD (fatal or nonfatal myocardial infarction or stroke) were assessed over >10 years of follow-up. Multivariable analyses for the primary global CVD end point adjusted for traditional risk factors plus statin use and creatinine (base model). RESULTS: Each test result was independently associated with global composite CVD events in MESA after adjustment for the components of the base model and the other test results (P<0.05 for each). When the 5 tests were added to the base model, the c-statistic improved from 0.74 to 0.79 (P=0.001), significant integrated discrimination improvement (0.07, 95% confidence interval [CI] 0.06-0.08, P<0.001) and category free net reclassification improvement (0.47; 95% CI, 0.38-0.56; P=0.003) were observed, and the model was well calibrated (χ2=12.2, P=0.20). Using a simple integer score counting the number of abnormal tests, compared with those with a score of 0, global CVD risk was increased among participants with a score of 1 (adjusted hazard ratio, 1.9; 95% CI, 1.4-2.6), 2 (hazard ratio, 3.2; 95% CI, 2.3-4.4), 3 (hazard ratio, 4.7; 95% CI, 3.4-6.5), and ≥4 (hazard ratio, 7.5; 95% CI, 5.2-10.6). Findings replicated in the Dallas Health Study were similar for the ASCVD outcome. CONCLUSIONS: Among adults without known CVD, a novel multimodality testing strategy using left ventricular hypertrophy by ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein significantly improved global CVD and ASCVD risk assessment.
Authors: Philip Greenland; Joseph S Alpert; George A Beller; Emelia J Benjamin; Matthew J Budoff; Zahi A Fayad; Elyse Foster; Mark A Hlatky; John McB Hodgson; Frederick G Kushner; Michael S Lauer; Leslee J Shaw; Sidney C Smith; Allen J Taylor; William S Weintraub; Nanette K Wenger; Alice K Jacobs Journal: Circulation Date: 2010-11-15 Impact factor: 29.690
Authors: Christopher R deFilippi; James A de Lemos; Robert H Christenson; John S Gottdiener; Willem J Kop; Min Zhan; Stephen L Seliger Journal: JAMA Date: 2010-11-15 Impact factor: 56.272
Authors: J Jeffrey Carr; Jennifer Clark Nelson; Nathan D Wong; Michael McNitt-Gray; Yadon Arad; David R Jacobs; Stephan Sidney; Diane E Bild; O Dale Williams; Robert C Detrano Journal: Radiology Date: 2005-01 Impact factor: 11.105
Authors: Justin T Saunders; Vijay Nambi; James A de Lemos; Lloyd E Chambless; Salim S Virani; Eric Boerwinkle; Ron C Hoogeveen; Xiaoxi Liu; Brad C Astor; Thomas H Mosley; Aaron R Folsom; Gerardo Heiss; Josef Coresh; Christie M Ballantyne Journal: Circulation Date: 2011-03-21 Impact factor: 29.690
Authors: Susan G Lakoski; Mary Cushman; Michael Criqui; Tatjana Rundek; Roger S Blumenthal; Ralph B D'Agostino; David M Herrington Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: Raimund Erbel; Stefan Möhlenkamp; Susanne Moebus; Axel Schmermund; Nils Lehmann; Andreas Stang; Nico Dragano; Dietrich Grönemeyer; Rainer Seibel; Hagen Kälsch; Martina Bröcker-Preuss; Klaus Mann; Johannes Siegrist; Karl-Heinz Jöckel Journal: J Am Coll Cardiol Date: 2010-10-19 Impact factor: 24.094
Authors: Javed Butler; Andreas Kalogeropoulos; Vasiliki Georgiopoulou; Rhonda Belue; Nicolas Rodondi; Melissa Garcia; Douglas C Bauer; Suzanne Satterfield; Andrew L Smith; Viola Vaccarino; Anne B Newman; Tamara B Harris; Peter W F Wilson; Stephen B Kritchevsky Journal: Circ Heart Fail Date: 2008-07 Impact factor: 8.790
Authors: Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245
Authors: Mark D Huffman; Jarett D Berry; Hongyan Ning; Alan R Dyer; Daniel B Garside; Xuan Cai; Martha L Daviglus; Donald M Lloyd-Jones Journal: J Am Coll Cardiol Date: 2013-04-09 Impact factor: 24.094
Authors: Wojciech Szczeklik; Yannick LeManach; Jakub Fronczek; Kamil Polok; David Conen; Finlay A McAlister; Sadeesh Srinathan; Pablo Alonso-Coello; Bruce Biccard; Emmanuelle Duceppe; Diane Heels-Ansdell; Jacek Górka; Shirley Pettit; Pavel S Roshanov; P J Devereaux Journal: CMAJ Date: 2020-12-07 Impact factor: 8.262
Authors: Ambarish Pandey; Kershaw V Patel; Wanpen Vongpatanasin; Colby Ayers; Jarett D Berry; Robert J Mentz; Michael J Blaha; John W McEvoy; Paul Muntner; Muthiah Vaduganathan; Adolfo Correa; Javed Butler; Daichi Shimbo; Vijay Nambi; Christopher deFilippi; Stephen L Seliger; Christie M Ballantyne; Elizabeth Selvin; James A de Lemos; Parag H Joshi Journal: Circulation Date: 2019-11-11 Impact factor: 29.690
Authors: Alana A Lewis; Colby R Ayers; Elizabeth Selvin; Ian Neeland; Christie M Ballantyne; Vijay Nambi; Ambarish Pandey; Tiffany M Powell-Wiley; Mark H Drazner; Mercedes R Carnethon; Jarett D Berry; Stephen L Seliger; Christopher R DeFilippi; James A de Lemos Journal: Circulation Date: 2020-01-14 Impact factor: 29.690
Authors: Anum Saeed; Vijay Nambi; Wensheng Sun; Salim S Virani; George E Taffet; Anita Deswal; Elizabeth Selvin; Kunihiro Matsushita; Lynne E Wagenknecht; Ron Hoogeveen; Josef Coresh; James A de Lemos; Christie M Ballantyne Journal: J Am Coll Cardiol Date: 2018-03-10 Impact factor: 24.094
Authors: Janice M Bonsu; Avirup Guha; Lawrence Charles; Vedat O Yildiz; Lai Wei; Brandee Baker; Jonathan E Brammer; Farrukh Awan; Maryam Lustberg; Raquel Reinbolt; Eric D Miller; Hani Jneid; Patrick Ruz; Rebecca R Carter; Michael W Milks; Electra D Paskett; Daniel Addison Journal: J Am Coll Cardiol Date: 2020-02-18 Impact factor: 24.094
Authors: Saro H Armenian; Dongyun Yang; Jennifer Berano Teh; Liezl C Atencio; Alicia Gonzales; F Lennie Wong; Wendy M Leisenring; Stephen J Forman; Ryotaro Nakamura; Eric J Chow Journal: Blood Adv Date: 2018-07-24
Authors: Daniel E Forman; James A de Lemos; Leslee J Shaw; David B Reuben; Radmila Lyubarova; Eric D Peterson; John A Spertus; Susan Zieman; Marcel E Salive; Michael W Rich Journal: J Am Coll Cardiol Date: 2020-09-29 Impact factor: 24.094